OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 43.6% in January

OnKure Therapeutics, Inc. (NASDAQ:OKUR) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 14,187 shares, a growth of 43.6% from the January 15th total of 9,877 shares. Based on an average daily trading volume, of 68,471 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the company’s shares are short sold. Currently, 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 68,471 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On OnKure Therapeutics

A number of institutional investors have recently modified their holdings of the company. Prosight Management LP increased its position in shares of OnKure Therapeutics by 204.9% during the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares during the period. Jane Street Group LLC bought a new stake in OnKure Therapeutics during the fourth quarter valued at $56,000. Renaissance Technologies LLC grew its holdings in OnKure Therapeutics by 40.7% during the 4th quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock worth $717,000 after acquiring an additional 71,600 shares during the period. Rosalind Advisors Inc. bought a new position in shares of OnKure Therapeutics in the 4th quarter worth about $2,118,000. Finally, Shay Capital LLC lifted its stake in shares of OnKure Therapeutics by 17.4% in the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after purchasing an additional 135,888 shares during the period. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Price Performance

Shares of OKUR opened at $2.42 on Friday. The business has a 50-day moving average of $2.87 and a 200-day moving average of $2.80. The company has a market capitalization of $32.79 million, a price-to-earnings ratio of -0.51 and a beta of 0.46. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $6.18.

Analysts Set New Price Targets

Several equities research analysts recently commented on OKUR shares. Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $32.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.